HOME >> BIOLOGY >> NEWS
Early Tests Indicate Motor Skills Unharmed In Consumers Of Tainted Fish

CHAMPAIGN, Ill. -- Preliminary but cautiously given good news for aging Great Lakes fish-eaters: First-round tests of fine motor skills showed barely a hint that years of consuming PCB- and DDE-contaminated fish have had any negative effects.

The study, when completed, will provide a rare, comprehensive look at the effects of environmental contaminants on older people. Scientists began a neurological assessment in 1992 of a group of men and women older than age 50 who have consumed 24 or more pounds of sport-caught Lake Michigan fish annually since the 1960s. A comparable group from the same region who didn't eat fish also is being studied. The fish-eaters have elevated levels of several contaminants, including PCBs and DDE (a derivative of the pesticide DDT).

Preliminary test results of dexterity and hand steadiness were presented May 12-15 in Montreal during Health Conference '97, which was devoted to pollution of the Great Lakes Basin. An overview of the project -- funded by the Agency for Toxic Substances and Disease Registry of the U.S. Department of Health and Human Services -- was published last year in the journal Toxicology and Industrial Health.

"People eating fish in the 1960s and '70s were really getting the highest level of exposure," said principal investigator Susan L. Schantz, a professor of environmental toxicology at the University of Illinois. "PCBs and DDE are not very easily metabolized; they tend to accumulate in body fat."

Animal research has shown that PCBs (polychlorinated biphenyls) -- a group of industrial chemicals toxic in the environment -- decrease dopamine levels in the brain. In Parkinson's disease, too little dopamine contributes to a reduction of motor function and executive abilities (planning and attention).

"We thought that we might see reduced motor function," she said. "At this point, however, it doesn't look like it. We've only looked at two of a large number of tests that we have yet to
'"/>

Contact: Jim Barlow, Life Sciences Editor
b-james3@uiuc.edu
217-333-5802
University of Illinois at Urbana-Champaign
3-Jun-1997


Page: 1 2

Related biology news :

1. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
2. Early detection hope for eye disease
3. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
4. Early dexamethasone exposure has long-term neurodevelopment, neuroendocrine effects
5. Early predictor of breast cancer aggressiveness
6. Early treatment confirmed as key to stroke recovery
7. Early identification of kidney disease cost-effective only when directed at high-risk patients
8. Early promise for treatment of Ebola
9. Early treatment can prevent severe vision loss in premature infants
10. Early hominids may have behaved more human than we had thought
11. Early infection and rejection detection

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Early Tests Indicate Motor Skills Unharmed Consumers Tainted Fish

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: